We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

48 hedge funds and large institutions have $136M invested in SAB Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

141% more capital invested

Capital invested by funds: $56.3M → $136M (+$79.6M)

41% more funds holding

Funds holding: 34 → 48 (+14)

192.84% less ownership

Funds ownership: 269.17% → 76.34% (-193%)

Holders
48
Holders Change
+14
Holders Change %
+41.18%
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
11
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
+$7.05M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$4.87M
3
PA
Perceptive Advisors
New York
+$2.64M
4
PBM
Propel Bio Management
California
+$2.15M
5
JFG
Jefferies Financial Group
New York
+$1.91M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$1.87M
2
SFM
Sphera Funds Management
Israel
-$1.14M
3
Renaissance Technologies
Renaissance Technologies
New York
-$162K
4
VF
Virtu Financial
New York
-$40K
5
Kovitz Investment Group Partners
Kovitz Investment Group Partners
Illinois
-$38.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$42.7M – – –
CC
2
Commodore Capital
New York
$16.5M – – –
RCM
3
RA Capital Management
Massachusetts
$16.5M – – –
WP
4
Woodline Partners
California
$10.7M – – –
SSC
5
Spruce Street Capital
New York
$8.22M +$7.23M +2,198,502 New
SC
6
Sessa Capital
New York
$8.22M – – –
Blackstone Inc
7
Blackstone Inc
New York
$8.02M +$7.05M +2,143,585 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$6.91M +$4.87M +1,481,383 +405%
PA
9
Perceptive Advisors
New York
$3M +$2.64M +803,210 New
PBM
10
Propel Bio Management
California
$2.44M +$2.15M +652,881 New
JFG
11
Jefferies Financial Group
New York
$2.17M +$1.91M +580,328 New
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$1.78M +$1.56M +475,439 New
Millennium Management
13
Millennium Management
New York
$1.21M +$1.07M +324,090 New
HWM
14
HB Wealth Management
Georgia
$1.15M – – –
Ameriprise
15
Ameriprise
Minnesota
$1.06M +$933K +283,645 New
Marshall Wace
16
Marshall Wace
United Kingdom
$884K +$778K +236,460 New
SAM
17
Simplify Asset Management
Nevada
$779K +$685K +208,227 New
AIC
18
AWM Investment Company
New York
$748K – – –
SC
19
Stempoint Capital
New York
$548K +$482K +146,558 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$447K +$111K +33,799 +39%
ECM
21
ExodusPoint Capital Management
New York
$322K +$283K +86,113 New
Goldman Sachs
22
Goldman Sachs
New York
$192K +$132K +40,127 +358%
Pathstone Holdings
23
Pathstone Holdings
New Jersey
$189K – – –
OAC
24
OMERS Administration Corp
Ontario, Canada
$157K +$138K +42,000 New
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
$116K +$102K +31,147 New
1
2 3

SABS Hedge Fund Activity: Q4 2025 in Review

48 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2025, worth a combined $136M — up 141% from $56.3M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SABS positions and 7 closed out — a net gain of 14 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was Blackstone Inc, opening a new position worth an estimated $7.05M. The largest seller was BVF Inc, exiting entirely with an estimated $1.87M sold.

  • 48 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2025, up from 34 in Q3 2025.
  • Funds reported $136M of SAB Biotherapeutics stock for Q4 2025, up 141% quarter-over-quarter.
  • 21 funds opened new SAB Biotherapeutics positions in Q4 2025 and 7 closed out, a net change of +14 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2025 was Blackstone Inc, an estimated $7.05M added.
  • The largest SAB Biotherapeutics seller in Q4 2025 was BVF Inc, an estimated $1.87M sold.

Based on aggregated 13F filings for Q4 2025.